# Pepticom

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pepticom

- Industry: Pharmaceuticals
- Headquarters: Jerusalem, Israel
- Website: www.pepticom.com/
- Total disclosed funding: $5M
- Latest round: Series A (Oct 24, 2019)
- Investors on record: 1

## About

Pepticom Ltd., based in Israel, leverages artificial intelligence to innovate peptide therapeutics aimed at addressing challenging medical conditions, including plaque psoriasis, through advanced drug design and optimization.Founded in 2011 in Jerusalem, Israel, Pepticom Ltd. specializes in AI-driven peptide therapeutics. The firm has completed 3 funding deals, with the latest being a Series A round of USD 6.6 mn led by Japan-Israel Hi-Tech Ventures on January 7, 2025. The company's founders, Anwar Rayan and Immanuel Lerner, have backgrounds in technology and business, focusing on developing novel solutions for drug discovery.Pepticom specializes in developing innovative peptide therapeutics using advanced AI technologies. Their products focus on designing and optimizing therapeutic peptides to target previously undruggable medical conditions, specifically for treating plaque psoriasis through oral IL-17 inhibitors. The company's proprietary computational AI platform facilitates the rapid prototyping of peptide candidates, utilizing both natural and synthetic amino acids while integrating reinforcement learning to enhance therapeutic efficacy and bioavailability. Pepticom primarily serves pharmaceutical companies seeking advanced therapeutic options across North America, Europe, and Asia.Pepticom generates revenue through strategic partnerships, collaborations, and licensing agreements with major pharmaceutical companies. These partnerships involve tailored peptide design services and licensing of proprietary technologies for drug discovery. Revenue streams include milestone payments during drug development and royalties upon successful product commercialization, with a focus on peptide therapeutics targeting conditions like plaque psoriasis.In January 2024, Pepticom Ltd. raised USD 6.6 mn in Series A funding led by Japan-Israel Hi-Tech Ventures, which it will use to advance drug discovery efforts. The company plans to develop new peptide therapeutics targeting additional unmet medical needs and expand its market presence into North America, Europe, and Asia by 2025, leveraging its AI platform to increase the efficiency and effectiveness of its drug development process.

## Funding rounds

- Series A, Oct 24, 2019, $5M — Chartered Group

## Investors

- Chartered Group (https://capitalatlas.ai/funds/chartered-group) — Series A